<code id='28D6B0E24A'></code><style id='28D6B0E24A'></style>
    • <acronym id='28D6B0E24A'></acronym>
      <center id='28D6B0E24A'><center id='28D6B0E24A'><tfoot id='28D6B0E24A'></tfoot></center><abbr id='28D6B0E24A'><dir id='28D6B0E24A'><tfoot id='28D6B0E24A'></tfoot><noframes id='28D6B0E24A'>

    • <optgroup id='28D6B0E24A'><strike id='28D6B0E24A'><sup id='28D6B0E24A'></sup></strike><code id='28D6B0E24A'></code></optgroup>
        1. <b id='28D6B0E24A'><label id='28D6B0E24A'><select id='28D6B0E24A'><dt id='28D6B0E24A'><span id='28D6B0E24A'></span></dt></select></label></b><u id='28D6B0E24A'></u>
          <i id='28D6B0E24A'><strike id='28D6B0E24A'><tt id='28D6B0E24A'><pre id='28D6B0E24A'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:focus    Page View:86
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In